Resorcinol

Resorcinol

SCHEMBL326229

Oc1cccc(O)c1.Oc1cccc(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 1.00
CA2 P00918 4/20 1.00
CA9 Q16790 4/20 1.00
CA14 Q9ULX7 3/20 1.00
ALDH1A1 P00352 3/20 1.00
CYP3A4 P08684 3/20 1.00
LMNA P02545 1/20 1.00
CA5A P35218 1/20 1.00
HSD17B10 Q99714 1/20 1.00
CA5B Q9Y2D0 1/20 1.00
HSD17B1 P14061 4/20 0.61
HSD17B2 P37059 4/20 0.61
CA1 P00915 3/20 0.61
TSHR P16473 3/20 0.61
TDP1 Q9NUW8 2/20 0.61
ACHE P22303 2/20 0.61
CYP2C9 P11712 1/20 0.61
CA7 P43166 1/20 0.61
LCK P06239 1/20 0.57
ENPP2 Q13822 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Resorcinol SCHEMBL15515 1.00
Resorcinol SCHEMBL3984288 0.96 CA12 (0.92) CA12CA2CA9CA14ALDH1A1
Resorcinol SCHEMBL5867187 0.96
Resorcinol SCHEMBL8442393 0.96
Resorcinol SCHEMBL8829963 0.96
Resorcinol SCHEMBL971994 0.96
Resorcinol SCHEMBL11679916 0.96 CA12 (0.92) CA12CA2CA9CA14ALDH1A1
Resorcinol SCHEMBL563023 0.96 CA12 (0.92) CA12CA2CA9CA14ALDH1A1
Resorcinol SCHEMBL20577903 0.96
Resorcinol SCHEMBL8517218 0.96 CA12 (0.92) CA12CA2CA9CA14ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7811711-B2 Formed by fusion with carbon fibers, gelation, supercritical solvent extraction, and pyrolysis; for electrolytic fuel cells and batteries Lawrennce Livermore National Security, LLC (US) 2010-10-12 US claimed
US-20090032770-A1 Insoluble and Branched Polyphosphonates and Methods Related Thereto FRX POLYMERS, LLC (US) 2009-02-05 US claimed
US-20090017339-A1 Formed by fusion with carbon fibers, gelation, supercritical solvent extraction, and pyrolysis; for electrolytic fuel cells and batteries LAWRENCE LIVERMORE NATIONAL SECURITY, LLC 2009-01-15 US claimed
US-7410718-B2 Formed by fusion with carbon fibers, gelation, supercritical solvent extraction, and pyrolysis; for electrolytic fuel cells and batteries LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) 2008-08-12 US claimed
US-20060258762-A1 Hydrocarbon or hydrofluorocarbon blown ASTM E-84 class I rigid polyurethane foams BAYER MATERIALSCIENCE LLC 2006-11-16 US claimed
CN-1583696-A Preparation of bisphenols salts CHANGCHUN APPLIED CHEMISTRY (CN) 2005-02-23 CN claimed
EP-0711744-B1 Method for making acyl substituted resorcinols GEN ELECTRIC (US) 2000-04-05 EP claimed
EP-0043680-B1 PROCESS FOR REMOVING CONTAMINANTS FROM A TIN SURFACE AMCHEM PRODUCTS, INC. (US) 1984-12-05 EP claimed
EP-3684762-B1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2023-05-03 EP disclosed
EP-1556009-B2 COSMETIC AND PHARMACEUTICAL FOAM FOAMIX PHARMACEUTICALS LTD (IL) 2021-07-21 EP disclosed
US-11062794-B2 Olfactory signature and odorant mixture having the same YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) 2021-07-13 US disclosed
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER LEAD DISCOVERY CENTER GMBH (DE) 2020-09-17 US disclosed
EP-3706709-A1 DENTAL COMPOSITION WITH HIGH E-MODULUS 3M Innovative Properties Company (US) 2020-09-16 EP disclosed
EP-3684762-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER Lead Discovery Center GmbH (DE) 2020-07-29 EP disclosed
US-4442163-A IMPROVED ADHESION OF RUBBER VULCANIZATES DEGUSSA AKTIENGESELLSCHAFT (DE) 1984-04-10 US disclosed
US-4426313-A Preparation of surfactants by sulfonating derivatives of depolymerized coal UOP INC. (US) 1984-01-17 US disclosed
US-4381949-A IMPROVED ADHESION TO RUBBER REINFORECMENT DEGUSSA AKTIENGESELLSCHAFT (DE) 1983-05-03 US disclosed
US-4283567-A FROM HIGH BOILING BY-PRODUCTS IN THE PRESENCE OF AMMONIUM SULFATE OR BISULFATE MITSUI PETROCHEMICAL INDUSTRIES LTD. (JP) 1981-08-11 US disclosed
US-3968174-A MULTISTAGE HALCON INTERNATIONAL, INC. (US) 1976-07-06 US disclosed
US-3965033-A Process for the production of oil-containing microcapsules FUJI PHOTO FILM CO., LTD. (JA) 1976-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200291011-A1 COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER POLRMT, UQCRC2, UQCRC1 CA12 4467/4885CA2 4068/4885CA9 3495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.